Data from the Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, provides an update on this study and how he anticipates the results will change the treatment of CLL.
